Osvaldo Mazza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Osvaldo Mazza has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Marianna Mazza
Department of Neuroscience, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy
28 shared publications - Giuseppe Marano
Department of Neuroscience, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy
27 shared publications - Gianandrea Traversi
Unit of Medical Genetics, Department of Laboratory Medicine, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy
26 shared publications - Eleonora Gaetani
Department of Translational Medicine and Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
16 shared publications - Esmeralda Capristo
Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
8 shared publications - Caterina Brisi
Department of Neuroscience, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy
7 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by MDPI AG in Metabolites
- Vol. 16 (11) , 871
Metabolic Signatures of Bipolar Disorder Through a Sex-Informed Lens: Emerging Biomarkers for Precision Psychiatry
Bipolar disorder (BD) is a clinically heterogeneous condition for which diagnosis, prognostic assessment, and treatment selection continue to rely predominantly on symptom-based evaluation. Metabolomics offers a promising approach to biomarker discovery by capturing the downstream effects of genetic susceptibility, environmental exposures, lifestyle, disease activity, and pharmacological treatment. Studies using peripheral biofluids, post-mortem brain tissue, and in vivo neurometabolic measures have identified alterations involving lipid metabolism, amino acids, energy production, oxidative stress, one-carbon metabolism, tryptophan–kynurenine pathways, and the gut microbiota-derived metabolome. Reproducibility is limited, and the potential influence of biological sex is frequently neglected or treated merely as a statistical covariate. This narrative review critically examines emerging metabolomic and lipidomic biomarkers in BD through a sex-informed perspective. We discuss their potential applications in differential diagnosis, mood-state characterization, illness staging, prediction of treatment response, and identification of cardiometabolic vulnerability. Particular attention is given to sex hormones, reproductive transitions, body composition, immune–metabolic regulation, circadian biology, and sex-dependent pharmacometabolic effects. Major methodological limitations, including small samples, medication exposure, inconsistent mood-state characterization, and insufficient sex-stratified validation, are also considered. Integrating sex as a biological variable into longitudinal, multi-omic, and clinically deeply phenotyped studies may improve biomarker reproducibility and support more individualized approaches to BD.
- 10 November 2026
- Published by MDPI AG in Metabolites
- Vol. 16 (11) , 871
Open AccessMetabolic Signatures of Bipolar Disorder Through a Sex-Informed Lens: Emerging Biomarkers for Precision Psychiatry
Bipolar disorder (BD) is a clinically heterogeneous condition for which diagnosis, prognostic assessment, and treatment selection continue to rely predominantly on symptom-based evaluation. Metabolomics offers a promising approach to biomarker discovery by capturing the downstream effects of genetic susceptibility, environmental exposures, lifestyle, disease activity, and pharmacological treatment. Studies using peripheral biofluids, post-mortem brain tissue, and in vivo neurometabolic measures have identified alterations involving lipid metabolism, amino acids, energy production, oxidative stress, one-carbon metabolism, tryptophan–kynurenine pathways, and the gut microbiota-derived metabolome. Reproducibility is limited, and the potential influence of biological sex is frequently neglected or treated merely as a statistical covariate. This narrative review critically examines emerging metabolomic and lipidomic biomarkers in BD through a sex-informed perspective. We discuss their potential applications in differential diagnosis, mood-state characterization, illness staging, prediction of treatment response, and identification of cardiometabolic vulnerability. Particular attention is given to sex hormones, reproductive transitions, body composition, immune–metabolic regulation, circadian biology, and sex-dependent pharmacometabolic effects. Major methodological limitations, including small samples, medication exposure, inconsistent mood-state characterization, and insufficient sex-stratified validation, are also considered. Integrating sex as a biological variable into longitudinal, multi-omic, and clinically deeply phenotyped studies may improve biomarker reproducibility and support more individualized approaches to BD.
- Open Access
- 22 October 2026
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 27 (5)
Microbiota Dysbiosis and the Gut-Brain Axis in Psychiatric Disorders: Molecular Mechanisms, Clinical Evidence, and Therapeutic Perspectives
The gut-brain axis provides a biologically plausible framework for understanding the bidirectional interactions among the intestinal microbiota, immune-inflammatory signaling, neuroendocrine regulation, neurotransmitter metabolism, and psychiatric symptoms. Although numerous recent reviews have examined individual psychiatric disorders, microbial composition, or microbiota-targeted therapies, the field still lacks a sufficiently integrated appraisal that clearly distinguishes associative findings from human studies, mechanistic evidence from preclinical research, and preliminary clinical interventions. This structured narrative review synthesizes clinical, translational, and preclinical studies across major depressive disorder, bipolar disorder, anxiety disorders, schizophrenia, and trauma-related conditions. The main literature search covered publications from January 2015 to January 2026; earlier foundational mechanistic studies of key relevance to gut–brain communication were also considered. Recurrent pathways include altered short-chain fatty acid production, tryptophan-kynurenine metabolism, immune-inflammatory activation, hypothalamic-pituitary-adrenal axis dysregulation, neurotransmitter-related signaling, impaired intestinal and blood-brain barrier integrity, and vagus nerve-mediated communication. Human studies predominantly demonstrate associations between microbial signatures and psychiatric phenotypes, symptom severity, inflammatory status, or treatment response, whereas preclinical models provide stronger mechanistic evidence that microbiota manipulation can influence behavioral, neurochemical, immune, and neuroendocrine outcomes. Probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation show therapeutic potential; however, the current evidence is limited by small sample sizes, methodological heterogeneity, insufficient standardization, and a lack of long-term validation. The distinctive contribution of this review is its structured comparison of three levels of evidence—human observational findings, experimental mechanistic studies, and emerging clinical interventions—thereby clarifying what has been consistently replicated, what remains mechanistically plausible, and what is not yet ready for routine application in psychiatric practice.
- 22 October 2026
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 27 (5)
Open AccessMicrobiota Dysbiosis and the Gut-Brain Axis in Psychiatric Disorders: Molecular Mechanisms, Clinical Evidence, and Therapeutic Perspectives
The gut-brain axis provides a biologically plausible framework for understanding the bidirectional interactions among the intestinal microbiota, immune-inflammatory signaling, neuroendocrine regulation, neurotransmitter metabolism, and psychiatric symptoms. Although numerous recent reviews have examined individual psychiatric disorders, microbial composition, or microbiota-targeted therapies, the field still lacks a sufficiently integrated appraisal that clearly distinguishes associative findings from human studies, mechanistic evidence from preclinical research, and preliminary clinical interventions. This structured narrative review synthesizes clinical, translational, and preclinical studies across major depressive disorder, bipolar disorder, anxiety disorders, schizophrenia, and trauma-related conditions. The main literature search covered publications from January 2015 to January 2026; earlier foundational mechanistic studies of key relevance to gut–brain communication were also considered. Recurrent pathways include altered short-chain fatty acid production, tryptophan-kynurenine metabolism, immune-inflammatory activation, hypothalamic-pituitary-adrenal axis dysregulation, neurotransmitter-related signaling, impaired intestinal and blood-brain barrier integrity, and vagus nerve-mediated communication. Human studies predominantly demonstrate associations between microbial signatures and psychiatric phenotypes, symptom severity, inflammatory status, or treatment response, whereas preclinical models provide stronger mechanistic evidence that microbiota manipulation can influence behavioral, neurochemical, immune, and neuroendocrine outcomes. Probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation show therapeutic potential; however, the current evidence is limited by small sample sizes, methodological heterogeneity, insufficient standardization, and a lack of long-term validation. The distinctive contribution of this review is its structured comparison of three levels of evidence—human observational findings, experimental mechanistic studies, and emerging clinical interventions—thereby clarifying what has been consistently replicated, what remains mechanistically plausible, and what is not yet ready for routine application in psychiatric practice.
- Open Access
Climate Change as a Chronic Stressor: Biological and Psychological Pathways Linking Environmental Change to Human Well-Being
Climate-related hazards are associated with adverse mental and physical health outcomes, but exposure-specific human findings are often discussed together with general stress mechanisms without clearly distinguishing their evidentiary strength. This narrative review addresses that gap by examining climate change as a context for recurrent thermal, disaster-related, and psychosocial stress, rather than as a single measurable exposure. Evidence is organized around three interacting biological domains: neuroendocrine regulation, inflammation and oxidative stress, and neuroplasticity. Human observational studies support associations between heat, extreme events, and mental health outcomes; short-term human experiments and animal models provide mechanistic insights but do not establish a chronic biological mediation pathway from climate change to psychiatric illness. Indirect pathways include displacement, livelihood disruption, loss, and anticipatory distress. Air pollution is treated as an interacting exposure with both climate-related and independent determinants. Eco-anxiety, climate anxiety, eco-distress, and ecological grief are distinguished from diagnosable disorders, with clinical relevance assessed through functional impairment and individual context. The review’s contribution is an evidence-qualified framework linking exposure timing, biological plausibility, psychosocial appraisal, and unequal adaptive capacity. Practical implications include contextual mental health assessment, continuity of psychiatric care during heat and disasters, and incorporation of psychosocial support into adaptation planning. The proposed framework remains hypothesis-generating and requires prospective testing with repeated exposure, biomarker, and clinical assessments.
Open AccessClimate Change as a Chronic Stressor: Biological and Psychological Pathways Linking Environmental Change to Human Well-Being
Climate-related hazards are associated with adverse mental and physical health outcomes, but exposure-specific human findings are often discussed together with general stress mechanisms without clearly distinguishing their evidentiary strength. This narrative review addresses that gap by examining climate change as a context for recurrent thermal, disaster-related, and psychosocial stress, rather than as a single measurable exposure. Evidence is organized around three interacting biological domains: neuroendocrine regulation, inflammation and oxidative stress, and neuroplasticity. Human observational studies support associations between heat, extreme events, and mental health outcomes; short-term human experiments and animal models provide mechanistic insights but do not establish a chronic biological mediation pathway from climate change to psychiatric illness. Indirect pathways include displacement, livelihood disruption, loss, and anticipatory distress. Air pollution is treated as an interacting exposure with both climate-related and independent determinants. Eco-anxiety, climate anxiety, eco-distress, and ecological grief are distinguished from diagnosable disorders, with clinical relevance assessed through functional impairment and individual context. The review’s contribution is an evidence-qualified framework linking exposure timing, biological plausibility, psychosocial appraisal, and unequal adaptive capacity. Practical implications include contextual mental health assessment, continuity of psychiatric care during heat and disasters, and incorporation of psychosocial support into adaptation planning. The proposed framework remains hypothesis-generating and requires prospective testing with repeated exposure, biomarker, and clinical assessments.
- Open Access
- 28 September 2026
- Published by MDPI AG in Behavioral Sciences
- Vol. 16 (10) , 1764
Trauma, Hyperarousal, and Sleep: Neurobehavioral Pathways in Affective Disorders
Sleep disturbances are common across affective disorders and may coexist with traumatic stress and persistent hyperarousal. This narrative review examines how trauma-related hyperarousal and sleep dysfunction are associated with major depressive disorder (MDD) and bipolar disorder (BD), while distinguishing observed associations from proposed mechanisms. A targeted search of PubMed, Scopus, and Google Scholar identified clinical, neurobiological, and translational literature on trauma, hyperarousal, insomnia, nightmares, circadian disruption, MDD, and BD. The evidence supports a multidimensional view of hyperarousal involving partly overlapping autonomic, cognitive–attentional, affective, and behavioral domains; however, it does not establish hyperarousal as a unitary mechanism or justify equating trauma-related vigilance with manic activation. Sleep disturbance may function as a symptom, vulnerability factor, or prodromal change, but no single sleep measure is currently a validated individual-level prognostic marker. Clinically, trauma history, sleep phenotype, affective state, comorbidity, medication effects, and current safety should be assessed jointly. Cognitive behavioral therapy for insomnia and established trauma-focused treatments have the strongest clinical basis within their indicated populations, whereas imagery rehearsal therapy, prazosin, chronobiological strategies, and candidate biomarkers require diagnosis-specific and evidence-graded interpretation. Longitudinal studies integrating objective sleep measures and explicit temporal modeling are needed before proposed pathways or precision approaches can be considered clinically validated.
- 28 September 2026
- Published by MDPI AG in Behavioral Sciences
- Vol. 16 (10) , 1764
Open AccessTrauma, Hyperarousal, and Sleep: Neurobehavioral Pathways in Affective Disorders
Sleep disturbances are common across affective disorders and may coexist with traumatic stress and persistent hyperarousal. This narrative review examines how trauma-related hyperarousal and sleep dysfunction are associated with major depressive disorder (MDD) and bipolar disorder (BD), while distinguishing observed associations from proposed mechanisms. A targeted search of PubMed, Scopus, and Google Scholar identified clinical, neurobiological, and translational literature on trauma, hyperarousal, insomnia, nightmares, circadian disruption, MDD, and BD. The evidence supports a multidimensional view of hyperarousal involving partly overlapping autonomic, cognitive–attentional, affective, and behavioral domains; however, it does not establish hyperarousal as a unitary mechanism or justify equating trauma-related vigilance with manic activation. Sleep disturbance may function as a symptom, vulnerability factor, or prodromal change, but no single sleep measure is currently a validated individual-level prognostic marker. Clinically, trauma history, sleep phenotype, affective state, comorbidity, medication effects, and current safety should be assessed jointly. Cognitive behavioral therapy for insomnia and established trauma-focused treatments have the strongest clinical basis within their indicated populations, whereas imagery rehearsal therapy, prazosin, chronobiological strategies, and candidate biomarkers require diagnosis-specific and evidence-graded interpretation. Longitudinal studies integrating objective sleep measures and explicit temporal modeling are needed before proposed pathways or precision approaches can be considered clinically validated.
- Open Access
Time Toxicity in Advanced Breast Cancer: Psychological Burden, Psychiatric Vulnerability, and Implications for Patient-Centered Decision-Making
The paradigm shift toward precision oncology in advanced breast cancer has increased therapeutic complexity, prolonging survival for many patients while simultaneously expanding the temporal burden associated with cancer care. Time toxicity, defined as the cumulative time spent receiving, accessing, coordinating, and recovering from medical interventions, is increasingly recognized as a clinically meaningful but still under-assessed dimension of patient-centered value. Beyond its organizational and economic implications, time toxicity may exert profound psychological and psychiatric effects, particularly in patients with advanced disease, for whom time represents not only a practical resource but also an existential, relational, and emotional domain. This narrative review examines how objective and subjective dimensions of time toxicity may inform patient-centered decision-making in advanced breast cancer. We summarize current evidence on the temporal demands of cancer care in advanced breast cancer and their psychological and relational consequences, focusing on how these factors can be discussed in patient-centered treatment decisions. From a value-based oncology perspective, the review examines how treatment optimization, subcutaneous formulations, oral therapies, telemedicine-based surveillance, decentralized care models, and early psycho-oncological assessment may reduce non-value-added time in clinical settings while preserving quality of care. Methodological challenges in measuring time toxicity and correlating it with overall survival, health-related quality of life, anxiety, depression, demoralization, and illness-related distress are also discussed. Incorporating time toxicity into shared decision-making may help clinicians move beyond traditional efficacy endpoints. It may support a more comprehensive approach in which survival benefit, psychological well-being, personal priorities, and the subjective value of time are considered together.
Open AccessTime Toxicity in Advanced Breast Cancer: Psychological Burden, Psychiatric Vulnerability, and Implications for Patient-Centered Decision-Making
The paradigm shift toward precision oncology in advanced breast cancer has increased therapeutic complexity, prolonging survival for many patients while simultaneously expanding the temporal burden associated with cancer care. Time toxicity, defined as the cumulative time spent receiving, accessing, coordinating, and recovering from medical interventions, is increasingly recognized as a clinically meaningful but still under-assessed dimension of patient-centered value. Beyond its organizational and economic implications, time toxicity may exert profound psychological and psychiatric effects, particularly in patients with advanced disease, for whom time represents not only a practical resource but also an existential, relational, and emotional domain. This narrative review examines how objective and subjective dimensions of time toxicity may inform patient-centered decision-making in advanced breast cancer. We summarize current evidence on the temporal demands of cancer care in advanced breast cancer and their psychological and relational consequences, focusing on how these factors can be discussed in patient-centered treatment decisions. From a value-based oncology perspective, the review examines how treatment optimization, subcutaneous formulations, oral therapies, telemedicine-based surveillance, decentralized care models, and early psycho-oncological assessment may reduce non-value-added time in clinical settings while preserving quality of care. Methodological challenges in measuring time toxicity and correlating it with overall survival, health-related quality of life, anxiety, depression, demoralization, and illness-related distress are also discussed. Incorporating time toxicity into shared decision-making may help clinicians move beyond traditional efficacy endpoints. It may support a more comprehensive approach in which survival benefit, psychological well-being, personal priorities, and the subjective value of time are considered together.
- Open Access
Modern Determinants of Earlier Menarche and Mental Health: A Translational Review for Clinicians
Background: Over the past decades, the global onset of menarche has progressively advanced, driven by complex interactions between metabolic, psychosocial, and environmental factors. Beyond its reproductive significance, menarche represents a critical developmental milestone that coincides with increased vulnerability to mental health difficulties. Contemporary determinants such as childhood obesity, early-life adversity, and exposure to endocrine-disrupting chemicals (EDCs) may accelerate pubertal timing while simultaneously shaping adverse psychological trajectories during adolescence. Objectives: This review aims to provide a translational and clinically oriented synthesis of modern determinants of earlier menarche and their associations with mental health outcomes in girls and adolescents, highlighting implications for early identification, prevention, and integrated clinical care. Methods: We conducted a narrative review mapping a scoping literature search conducted using PubMed/Medline, Scopus, and PsycINFO, focusing on literature from the last decade (2016–2026), with emphasis on systematic reviews, meta-analyses, and longitudinal cohort studies. Evidence was synthesized across biological, psychosocial, and environmental domains. Results: Accumulating evidence indicates that higher childhood adiposity, psychosocial stress, and EDC exposure are consistently associated with advanced pubertal timing. Earlier menarche correlates with an elevated risk of depressive symptoms, anxiety, self-harm, and body image-related distress, although effect sizes vary across populations. Emerging longitudinal data suggest that the peri-menarcheal period represents a critical window for symptom exacerbation. These associations appear to be mediated by biological mechanisms (e.g., hormonal shifts, hypothalamic–pituitary–adrenal (HPA) axis reactivity) and social processes including peer-comparison dynamics and premature sexualization. Conclusions: Earlier menarche acts as a biopsychosocial sentinel event rather than an isolated gynecological milestone. Integrating mental health screening and anticipatory guidance into pediatric and gynecological care is essential for early risk detection. A multidisciplinary, equity-oriented approach is required to address both individual vulnerability and broader environmental determinants.
Open AccessModern Determinants of Earlier Menarche and Mental Health: A Translational Review for Clinicians
Background: Over the past decades, the global onset of menarche has progressively advanced, driven by complex interactions between metabolic, psychosocial, and environmental factors. Beyond its reproductive significance, menarche represents a critical developmental milestone that coincides with increased vulnerability to mental health difficulties. Contemporary determinants such as childhood obesity, early-life adversity, and exposure to endocrine-disrupting chemicals (EDCs) may accelerate pubertal timing while simultaneously shaping adverse psychological trajectories during adolescence. Objectives: This review aims to provide a translational and clinically oriented synthesis of modern determinants of earlier menarche and their associations with mental health outcomes in girls and adolescents, highlighting implications for early identification, prevention, and integrated clinical care. Methods: We conducted a narrative review mapping a scoping literature search conducted using PubMed/Medline, Scopus, and PsycINFO, focusing on literature from the last decade (2016–2026), with emphasis on systematic reviews, meta-analyses, and longitudinal cohort studies. Evidence was synthesized across biological, psychosocial, and environmental domains. Results: Accumulating evidence indicates that higher childhood adiposity, psychosocial stress, and EDC exposure are consistently associated with advanced pubertal timing. Earlier menarche correlates with an elevated risk of depressive symptoms, anxiety, self-harm, and body image-related distress, although effect sizes vary across populations. Emerging longitudinal data suggest that the peri-menarcheal period represents a critical window for symptom exacerbation. These associations appear to be mediated by biological mechanisms (e.g., hormonal shifts, hypothalamic–pituitary–adrenal (HPA) axis reactivity) and social processes including peer-comparison dynamics and premature sexualization. Conclusions: Earlier menarche acts as a biopsychosocial sentinel event rather than an isolated gynecological milestone. Integrating mental health screening and anticipatory guidance into pediatric and gynecological care is essential for early risk detection. A multidisciplinary, equity-oriented approach is required to address both individual vulnerability and broader environmental determinants.
- Open Access
Sleep as a Transdiagnostic Target in Psychiatry: Prebiotics, the Gut–Brain Axis, and the Gap Between Mechanistic Plausibility and Clinical Evidence
Sleep disturbances are highly prevalent across psychiatric disorders and represent both a clinical feature and a potential transdiagnostic therapeutic target. Growing evidence suggests that the gut microbiota may contribute to sleep regulation through immune, metabolic, circadian, and neuroendocrine pathways. Prebiotics, defined as selectively utilized substrates that confer health benefits through modulation of host microorganisms, have received increasing attention as nutritional strategies capable of influencing the gut–brain axis. This narrative review summarizes preclinical and human evidence on prebiotic interventions in relation to sleep-related outcomes and psychiatric symptomatology, with particular attention to short-chain fatty acids, circadian regulation, inflammatory pathways, stress-related hypothalamic–pituitary–adrenal axis activity, and microbial metabolite signaling. Preclinical studies suggest that selected prebiotics may influence sleep architecture, stress resilience, neuroinflammation, and behavioral phenotypes, particularly under conditions of stress or sleep disruption, but translation to human populations remains preliminary. Available clinical studies are limited by small sample sizes, heterogeneous prebiotic formulations, variable doses and intervention durations, inconsistent microbiome methodologies, and frequent reliance on subjective sleep measures rather than polysomnography or actigraphy. Therefore, current evidence supports prebiotics as biologically plausible and generally well-tolerated adjunctive strategies, but not as established treatments for insomnia or psychiatric symptoms. Sleep may provide a clinically meaningful transdiagnostic framework for future nutritional psychiatry research, provided that adequately powered randomized controlled trials integrate objective sleep assessment, standardized microbiome and metabolomic profiling, and clinically relevant psychiatric outcomes.
Open AccessSleep as a Transdiagnostic Target in Psychiatry: Prebiotics, the Gut–Brain Axis, and the Gap Between Mechanistic Plausibility and Clinical Evidence
Sleep disturbances are highly prevalent across psychiatric disorders and represent both a clinical feature and a potential transdiagnostic therapeutic target. Growing evidence suggests that the gut microbiota may contribute to sleep regulation through immune, metabolic, circadian, and neuroendocrine pathways. Prebiotics, defined as selectively utilized substrates that confer health benefits through modulation of host microorganisms, have received increasing attention as nutritional strategies capable of influencing the gut–brain axis. This narrative review summarizes preclinical and human evidence on prebiotic interventions in relation to sleep-related outcomes and psychiatric symptomatology, with particular attention to short-chain fatty acids, circadian regulation, inflammatory pathways, stress-related hypothalamic–pituitary–adrenal axis activity, and microbial metabolite signaling. Preclinical studies suggest that selected prebiotics may influence sleep architecture, stress resilience, neuroinflammation, and behavioral phenotypes, particularly under conditions of stress or sleep disruption, but translation to human populations remains preliminary. Available clinical studies are limited by small sample sizes, heterogeneous prebiotic formulations, variable doses and intervention durations, inconsistent microbiome methodologies, and frequent reliance on subjective sleep measures rather than polysomnography or actigraphy. Therefore, current evidence supports prebiotics as biologically plausible and generally well-tolerated adjunctive strategies, but not as established treatments for insomnia or psychiatric symptoms. Sleep may provide a clinically meaningful transdiagnostic framework for future nutritional psychiatry research, provided that adequately powered randomized controlled trials integrate objective sleep assessment, standardized microbiome and metabolomic profiling, and clinically relevant psychiatric outcomes.
- Open Access
Digital Transition and Mental Health in School Settings: Does Handwriting Still Matter? A Multidisciplinary Perspective
Background/Objectives: The digital transition in school settings is reshaping children’s learning, writing practices, and mental health trajectories. This narrative review examines whether handwriting still matters in contemporary hybrid educational environments from a multidisciplinary perspective. Methods: Evidence from neuroscience, developmental psychology, educational sciences, pediatrics, and child psychiatry was narratively synthesized, with attention to handwriting, digital exposure, learning, emotional regulation, and vulnerable populations. Results: Handwriting uniquely integrates fine motor control, visuomotor coordination, orthographic processing, attention, and embodied cognition, supporting early literacy, memory consolidation, conceptual learning, and reflective writing. Conversely, excessive or poorly mediated digital exposure may interact with attentional fragmentation, sleep disruption, online stressors, problematic use, and internalizing symptoms, particularly in vulnerable children and adolescents. Digital tools remain essential for personalization, accessibility, and compensatory support, especially for students with neurodevelopmental or learning difficulties. Conclusions: Handwriting and digital technologies should not be framed as competing educational paradigms. A developmentally sensitive hybrid model is needed, preserving handwriting during key stages of literacy and self-regulation while integrating digital tools as purposeful, individualized resources for learning, inclusion, and school mental health promotion.
Open AccessDigital Transition and Mental Health in School Settings: Does Handwriting Still Matter? A Multidisciplinary Perspective
Background/Objectives: The digital transition in school settings is reshaping children’s learning, writing practices, and mental health trajectories. This narrative review examines whether handwriting still matters in contemporary hybrid educational environments from a multidisciplinary perspective. Methods: Evidence from neuroscience, developmental psychology, educational sciences, pediatrics, and child psychiatry was narratively synthesized, with attention to handwriting, digital exposure, learning, emotional regulation, and vulnerable populations. Results: Handwriting uniquely integrates fine motor control, visuomotor coordination, orthographic processing, attention, and embodied cognition, supporting early literacy, memory consolidation, conceptual learning, and reflective writing. Conversely, excessive or poorly mediated digital exposure may interact with attentional fragmentation, sleep disruption, online stressors, problematic use, and internalizing symptoms, particularly in vulnerable children and adolescents. Digital tools remain essential for personalization, accessibility, and compensatory support, especially for students with neurodevelopmental or learning difficulties. Conclusions: Handwriting and digital technologies should not be framed as competing educational paradigms. A developmentally sensitive hybrid model is needed, preserving handwriting during key stages of literacy and self-regulation while integrating digital tools as purposeful, individualized resources for learning, inclusion, and school mental health promotion.
- Open Access
- 1 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5117
Stratified Psychosocial Care in Assisted Reproductive Technologies: A Narrative Review and Conceptual Framework Across the IVF Pathway
Assisted reproductive technologies (ART), particularly in vitro fertilization (IVF), are characterized by substantial emotional burden, uncertainty, and repeated decision-making under probabilistic conditions. Although psychological distress is common among individuals and couples undergoing ART, psychosocial care remains inconsistently integrated into fertility pathways and is rarely tailored to individual needs. This narrative review synthesizes evidence concerning infertility-related distress, anxiety and depressive symptoms, couple functioning, treatment discontinuation, psychosocial screening, and psychological interventions across the IVF trajectory. Key phases of treatment, including pretreatment assessment, ovarian stimulation, embryo transfer, the waiting period, cycle outcome, and decisions regarding repetition or discontinuation, are described, and phase-specific psychological vulnerabilities are identified. On the basis of the available literature, we propose a conceptual stepped-care framework ranging from universal psychoeducation and routine monitoring to structured psychological interventions, couple-based care, and specialist psychiatric management. Practical screening thresholds, referral criteria, reassessment intervals, and a safety pathway for suicidal ideation are outlined. Particular attention is given to male-factor infertility, strategies for engaging male partners, and the ethical and data-governance requirements of digital mental health tools. Current evidence supports psychosocial interventions for improving emotional well-being and quality of life and suggests a potential role in treatment continuation, but their effects on pregnancy and live-birth outcomes remain uncertain. The proposed framework should therefore be regarded as a clinically informed conceptual model rather than a validated prediction algorithm. Prospective studies are required to assess its feasibility, predictive performance, cost-effectiveness, and impact on patient-centered outcomes.
- 1 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5117
Open AccessStratified Psychosocial Care in Assisted Reproductive Technologies: A Narrative Review and Conceptual Framework Across the IVF Pathway
Assisted reproductive technologies (ART), particularly in vitro fertilization (IVF), are characterized by substantial emotional burden, uncertainty, and repeated decision-making under probabilistic conditions. Although psychological distress is common among individuals and couples undergoing ART, psychosocial care remains inconsistently integrated into fertility pathways and is rarely tailored to individual needs. This narrative review synthesizes evidence concerning infertility-related distress, anxiety and depressive symptoms, couple functioning, treatment discontinuation, psychosocial screening, and psychological interventions across the IVF trajectory. Key phases of treatment, including pretreatment assessment, ovarian stimulation, embryo transfer, the waiting period, cycle outcome, and decisions regarding repetition or discontinuation, are described, and phase-specific psychological vulnerabilities are identified. On the basis of the available literature, we propose a conceptual stepped-care framework ranging from universal psychoeducation and routine monitoring to structured psychological interventions, couple-based care, and specialist psychiatric management. Practical screening thresholds, referral criteria, reassessment intervals, and a safety pathway for suicidal ideation are outlined. Particular attention is given to male-factor infertility, strategies for engaging male partners, and the ethical and data-governance requirements of digital mental health tools. Current evidence supports psychosocial interventions for improving emotional well-being and quality of life and suggests a potential role in treatment continuation, but their effects on pregnancy and live-birth outcomes remain uncertain. The proposed framework should therefore be regarded as a clinically informed conceptual model rather than a validated prediction algorithm. Prospective studies are required to assess its feasibility, predictive performance, cost-effectiveness, and impact on patient-centered outcomes.
- Open Access
- 13 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4603
Insomnia in Breast Cancer: A Neglected Symptom Cluster
Background/Objectives: Insomnia is one of the most prevalent and persistent symptoms among patients with breast cancer, yet it remains under-recognized and undertreated in routine clinical practice. Beyond its impact on sleep quality, insomnia is increasingly understood as a multidimensional condition involving neurobiological, psychological, and behavioral mechanisms, closely intertwined with cancer-related stress and psychiatric comorbidities. This narrative review aims to provide a comprehensive and integrative overview of insomnia in breast cancer, focusing on its epidemiology, pathophysiological underpinnings, neuropsychiatric correlates, and clinical implications, while highlighting gaps in current research and management. Methods: A narrative review of the literature was conducted, including studies published in major medical databases (PubMed, Scopus, and Web of Science) up to 2025. Relevant articles addressing insomnia, sleep disturbances, psychiatric symptoms, and neurobiological mechanisms in breast cancer populations were selected and synthesized. Results: Insomnia affects a substantial proportion of breast cancer patients across the disease trajectory, from diagnosis to survivorship. Its etiology is multifactorial, involving dysregulation of the hypothalamic–pituitary–adrenal axis, inflammatory processes, and circadian rhythm, as well as treatment-related factors such as chemotherapy, endocrine therapy, and menopausal symptoms. Insomnia frequently co-occurs with depression, anxiety, fatigue, and pain, forming symptom clusters that significantly impair quality of life and may influence clinical outcomes. Emerging evidence supports a bidirectional relationship between insomnia and psychiatric vulnerability, suggesting a shared neurobiological substrate within the brain–body stress axis. Conclusions: Insomnia in breast cancer should be conceptualized as a neuropsychiatric condition embedded within a broader stress-related symptom network rather than as an isolated sleep disturbance. Improved screening, interdisciplinary management, and the integration of evidence-based interventions such as cognitive behavioral therapy for insomnia are essential. Research should focus on personalized and mechanistically informed approaches to better address this highly prevalent yet insufficiently managed condition.
- 13 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4603
Open AccessInsomnia in Breast Cancer: A Neglected Symptom Cluster
Background/Objectives: Insomnia is one of the most prevalent and persistent symptoms among patients with breast cancer, yet it remains under-recognized and undertreated in routine clinical practice. Beyond its impact on sleep quality, insomnia is increasingly understood as a multidimensional condition involving neurobiological, psychological, and behavioral mechanisms, closely intertwined with cancer-related stress and psychiatric comorbidities. This narrative review aims to provide a comprehensive and integrative overview of insomnia in breast cancer, focusing on its epidemiology, pathophysiological underpinnings, neuropsychiatric correlates, and clinical implications, while highlighting gaps in current research and management. Methods: A narrative review of the literature was conducted, including studies published in major medical databases (PubMed, Scopus, and Web of Science) up to 2025. Relevant articles addressing insomnia, sleep disturbances, psychiatric symptoms, and neurobiological mechanisms in breast cancer populations were selected and synthesized. Results: Insomnia affects a substantial proportion of breast cancer patients across the disease trajectory, from diagnosis to survivorship. Its etiology is multifactorial, involving dysregulation of the hypothalamic–pituitary–adrenal axis, inflammatory processes, and circadian rhythm, as well as treatment-related factors such as chemotherapy, endocrine therapy, and menopausal symptoms. Insomnia frequently co-occurs with depression, anxiety, fatigue, and pain, forming symptom clusters that significantly impair quality of life and may influence clinical outcomes. Emerging evidence supports a bidirectional relationship between insomnia and psychiatric vulnerability, suggesting a shared neurobiological substrate within the brain–body stress axis. Conclusions: Insomnia in breast cancer should be conceptualized as a neuropsychiatric condition embedded within a broader stress-related symptom network rather than as an isolated sleep disturbance. Improved screening, interdisciplinary management, and the integration of evidence-based interventions such as cognitive behavioral therapy for insomnia are essential. Research should focus on personalized and mechanistically informed approaches to better address this highly prevalent yet insufficiently managed condition.